BLI-489

Class: Beta-lactamase inhibitor (carbapenem)

Details of activity:	β-lactamase inhibitor, inhibits class A, C and D β-lactamases
Combined with other compounds:	Was tested with pipercillin in murine modelswhich demonstrated a similar level of efficacy as pipercillin:tazobactam
Institute where first reported:	Wyeth Research (Pfizer, USA)
Year first mentioned:	2007
Highest developmental phase:	Phase 1
Development status:	Inactive
Reason Dropped:	Was in phase I trials with Wyeth, however, with Pfizer (purchased Wyeth in 2009) closed it's antibioitc research unit in 2011 (1,2).

Chemical structure(s):
Canonical SMILES:	C1COCC2=NC(=CN12)/C=C\3/C(=O)N4C(=CS[C@H]34)C(=O)[O-].[Na+]
Isomeric SMILES:	C1COCC2=NC(=CN21)/C=C/3\[C@@H]4N(C3=O)C(=CS4)C(=O)[O-].[Na+]
InChI:	InChI=1S/C13H11N3O4S.Na/c17-11-8(12-16(11)9(6-21-12)13(18)19)3-7-4-15-1-2-20-5-10(15)14-7;/h3-4,6,12H,1-2,5H2,(H,18,19);/q;+1/p-1/b8-3-;/t12-;/m1./s1
InChI Key:	RFSWVJXWZXQOSW-ZDFSRXSCSA-M
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/23697683

External links:
Guide to Pharmacology:	BLI-489 free acid
Citations:	http://aac.asm.org/content/53/2/370.short#fn-2 https://clinicaltrials.gov/ct2/show/NCT00894439